

## The Syntax Approach


The Syntax US Medical Innovation Index equally weights up to 50 US-listed companies engaged in the biotechnology and biopharma industry. To qualify, a company must pass the Index's screens for size and liquidity, and must own at least one drug that is in an FDA Phase II or Phase III trial and has a special FDA designation or a milestone in the near future.

The Index uses company classification data structured in Syntax's proprietary Functional Information System (FIS), which draws primarily from audited annual reports (e.g., 10-K filings) and secondarily from unaudited documents (e.g., news articles, company websites) to allow granular groupings and comparisons of companies by the characteristics of their various product lines.

## Index Information

Ticker Symbol:	SYUMIX
Total Return Ticker:	SYUMIXG
Benchmark:	NA
# Constituents:	48
Inception Date:	10/21/2022
Rebalancing Freq.:	Quarterly
First Index Value:	10/21/2022

## Performance: Growth of \$100



## Key Points

- Owners of drugs in FDA Phase II or III trials
- Focused on specially designated or soon-completing trials
- US listings only
- Sizes between \$500M and \$50B
- Equally weighted

Total return, gross of dividends, not including fees (periods greater than one year have been annualized). As of 03.31.2024.

## Index Return (%)

	YTD	1Q24	1Y	3Y	5Y	7Y	10Y	Since 10.21.22
US Medical Innovation	7.10	7.10	35.34	-	-	-	-	19.06

## About Syntax

Syntax LLC is a financial data and technology company that codifies business models. Syntax operates through three segments: Company Data, Wealth Technology, and Financial Indices. Using its patented FIS® technology inspired by systems sciences, the Company Data segment offers the most comprehensive, granular, and accurate product line revenue data available on the market. The Wealth Technology segment then uses this abundance of data to facilitate the instantaneous creation and ongoing management of direct indexing solutions and rules-based equity portfolios through a fully automated platform. The Financial Indices segment enables Syntax to deliver customized and proprietary indices, including core global benchmarks and micro- and macro-thematic, smart beta, defined outcome, and target volatility indices. These indices are foundational for a range of financial products, such as ETFs, UITs, and structured products. Learn more at [www.syntaxdata.com](http://www.syntaxdata.com).

For additional information, please visit [www.syntaxdata.com](http://www.syntaxdata.com)

## Annual Returns (%)

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
US Medical Innovation	16.32	-	-	-	-	-	-	-	-	-

## Index Statistics

	Vol.	Sharpe Ratio	Dividend Yield	P / E Ratio	P / B Ratio
US Medical Innovation	31.7	0.94	0.22	NA	6.26

\* Risk statistics use monthly data over last 1 years.

## Top 10 Holdings (%)

Company	Weight (%)
Avidity Biosciences Inc	4.31
MorphoSys AG	4.04
Iovance Biotherapeutics Inc	3.15
Tarsus Pharmaceuticals Inc	3.15
Geron Corp	3.11
Immunitybio Inc	2.67
REGENXBIO Inc.	2.67
Allogene Therapeutics Inc	2.66
Kura Oncology Inc	2.66
MannKind Corp	2.54

## Disclaimers

Past performance is no guarantee of future results. All performance presented prior to the index inception date is back-tested performance. Back-tested performance is not actual performance, but is hypothetical. The inception date of the Syntax US Medical Innovation Index is 21 October 2022. The Syntax US Medical Innovation Index is the property of Syntax LLC, which calculates and maintains the Index. Syntax®, Stratified®, Stratified Indices®, Stratified-Weight™, Stratified Benchmark Indices™, Stratified Sector Indices™, Stratified Thematic Indices™, and Locus® are trademarks or registered trademarks of Syntax, LLC and its affiliate Locus LP. FIS™ is a trademark of Syntax for Syntax's "Functional Information System."

Index performance does not represent actual fund or portfolio performance and such performance does not reflect the actual investment experience of any investor. An investor cannot invest directly in an index. In addition, the results actual investors might have achieved would have differed from those shown because of differences in the timing, amounts of their investments, and fees and expenses associated with an investment in a portfolio invested in accordance with an index. None of the Syntax Indices or the benchmark indices portrayed herein charge management fees or incur brokerage expenses, and no such fees or expenses were deducted from the performance shown; provided, however, that the returns of any investment portfolio invested in accordance with such indices would be net of such fees and expenses. Additionally, none of these indices lend securities, and no revenues from securities lending were added to the performance shown.

Beta is a measure of relative risk, calculated as the covariance of the Index with a benchmark divided by the variance of the benchmark. Volatility is the annualized standard deviation of index returns. Sharpe ratio is a risk-adjusted measure calculated using standard deviation and excess return to determine reward per unit of risk. A higher Sharpe ratio indicates better risk-adjusted performance. Tracking error is the annualized standard deviation of excess returns over the benchmark. Upside (downside) capture is the ratio of index return to benchmark return during months of positive (negative) benchmark performance. Beta, Volatility, Sharpe Ratio, Tracking Error, and Capture ratios are calculated using monthly data over the past ten years. Weighted Average Stock Price-to-Earnings Ratio (P/E Ratio) is the harmonic weighted average of the ratio of each stock's share price to its trailing 12 month earnings per share. Weighted Average Stock Price-to-Book-Value Ratio (P/B Ratio) is the harmonic weighted average of the ratio of each stock's market price to its net asset value. Dividend Yield is the weighted average of the ratio of each stock's annual dividend per share to its market price. Price-to-Earnings, Price-to-Book and Dividend Yield are calculated as of the factsheet period-end. Turnover shows the percentage of the index portfolio that was liquidated during the reconstitutions and rebalancings that occurred during the trailing year. P/E, P/B, and Dividend Yield are calculated by Syntax via Refinitiv.

This factsheet is for informational purposes only and is not intended to be, nor should it be construed or used as an offer to sell, or a solicitation of any offer to buy, any security. Additionally, the information herein is not intended to provide, and should not be relied upon for, legal advice or investment recommendations. You should make an independent investigation of the matters described herein, including consulting your own advisors on the matters discussed herein. In addition, certain information contained in this factsheet has been obtained from published and non-published sources prepared by other parties, which in certain cases have not been updated through the date hereof. While such information is believed to be reliable for the purpose used in this factsheet, such information has not been independently verified by Syntax and Syntax does not assume any responsibility for the accuracy or completeness of such information. Syntax LLC, its affiliates and their independent providers are not liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. Distribution of Syntax data and the use of Syntax indices to create financial products require a license with Syntax and/or its licensors. Investments are not FDIC insured, may lose value and have no bank guarantee.